Xiangxue Life Sciences
Guangzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biotech developing advanced cell and gene therapies, primarily CAR-T, for cancer treatment.
Oncology
Technology Platform
Platform for engineering autologous and allogeneic CAR-T and TCR-T cells with enhanced tumor targeting and safety profiles.
Opportunities
Potential to lead in developing effective CAR-T therapies for solid tumors, a massive unmet medical need.
Risk Factors
High clinical development costs and uncertain regulatory pathways for novel cell therapies in China and abroad.
Competitive Landscape
Competes with dozens of well-funded Chinese CAR-T biotechs like JW Therapeutics and Gracell, as well as global leaders.